BiotechTube

Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization + CsA with steroid minimization

ApprovedTerminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Adult-Onset

Conditions

Diabetes Mellitus, Adult-Onset

Trial Timeline

Feb 1, 2010 → Jun 1, 2015

NCT ID
NCT01002339

About Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization + CsA with steroid minimization

Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization + CsA with steroid minimization is a approved stage product being developed by Rafael Holdings for Diabetes Mellitus, Adult-Onset. The current trial status is terminated. This product is registered under clinical trial identifier NCT01002339. Target conditions include Diabetes Mellitus, Adult-Onset.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01002339ApprovedTerminated

Competing Products

20 competing products in Diabetes Mellitus, Adult-Onset

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Rafael Holdings

Varenicline + Nicotine patchApproved
77
Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acidApproved
77
inhaled corticosteroid plus LABA plus oral corticosteroidApproved
77
IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous PlaceboApproved
77
Insulin + insulinApproved
77